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Measure of benefit:
The benefit measures were life-years (LYs) and quality-adjusted life-years (QALYs). A 3.5% discount rate was applied.
Cost data:
The direct costs included drug costs, administration costs, those associated with receiving granulocyte colonystimulating factor (G-CSF), and those related to adverse events. Additionally, monitoring costs, hospital costs in relapsed patients, and the primary care costs post-relapse were considered. Adjuvant hormone and radiotherapy costs were excluded, as they did not differ between the groups. The resource use data for patients who relapsed were based on an observational data set collected at a UK university hospital. All prices were reported in 2005 UK pounds sterling (£) and in Euros (EUR) using market exchange rates. An annual discount rate of 3.5% was used.
Analysis of uncertainty:
Parameter uncertainty was investigated through the use of probabilistic sensitivity analysis, which was performed using 1,000 samples of the statistical distributions associated with the key model parameters. Additionally, the impact of using different methods for extrapolating the survival beyond the trial period, the impact of giving G-CSF prophylaxis to all TAC patients, subgroups and univariate analyses, and changing the time horizon were tested.
Results
The estimated mean LYs for the TAC cohort were 7.194, and for the FAC cohort were 6.821, an incremental LY gain of 0.374.
The estimated mean QALYs for the TAC cohort were 5.517, and for the FAC cohort were 5.201, an incremental gain of 0.317.
The mean total costs were £15,587 for TAC and £9,828 for FAC, which is an incremental cost of £5,759.
The incremental ratios from the probabilistic analysis were £15,400 (95% confidence interval, CI: £13,734, £17,997) per LY gained and £18,274 (95% CI: £14,161, £32,422) per QALY gained. Deterministic estimates were also presented.
The sensitivity analysis suggested that the most influential parameter was the time horizon: the cost per QALY was £58,201 at five years, and £9,865 for the lifetime analysis. The method used to extrapolate the trial outcomes beyond the available follow-up had an impact on the results, with a cost per QALY ranging from £15,588, when assuming a continuation of the treatment effect beyond the trial follow-up, to £28,782 per QALY, when assuming no continuation of the treatment effect.
The model was also sensitive to the extreme utility weights for patients in remission, and the scenario in which all TAC patients received primary prophylaxis with pegfilgrastim. The subgroup analysis suggested that TAC was more costeffective in patients who were younger, oestrogen-receptor-negative, and with fewer positive nodes and lower tumour grades.
Authors' conclusions
The authors concluded that adjuvant TAC was cost-effective compared with FAC in the UK, as well as TAC with primary G-CSF prophylaxis. The short-term disadvantages were small compared with the long-term benefits. The primary uncertainty in the analysis lay in the extrapolation of outcomes beyond the available trial follow-up data.
CRD commentary

Interventions:
The article provided adequate detail about the interventions compared. However, the authors stated that FAC was not commonly used in the UK and that they used this regimen as a proxy for fluorouracil, epirubicin, and cyclophosphamide (FEC). Whilst this claim was supported by references it is not clear why FEC was not included as a comparator.
